Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Michael Bukhalo MD SC

Neither a doctor nor a teaching hospital

Research payments

$868,239

97 payments

Through program year 2025, Michael Bukhalo MD SC is reported as receiving $868,239 in research payments, across 97 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $374,338 39
2024 Research $242,838 29
2023 Research $234,859 18
2022 Research $10,567 9
2019 Research $5,637 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $624,212 76 payments
  2. Acrotech Biopharma LLC $238,390 19 payments
  3. LEO Pharma AS $5,637 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis $164,466 9 payments
  2. 246-13651-302 $147,538 11 payments
  3. A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) $132,757 17 payments
  4. Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis $132,050 17 payments
  5. A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa $92,106 9 payments
  6. 246-13651-301 $84,184 6 payments
  7. M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa $20,596 2 payments
  8. M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) $17,207 2 payments
  9. A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis $14,590 1 payment
  10. A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa $14,527 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record